A Gilead Sciences scientist analyzes a patient’s antibody levels at the Gilead Laboratory in Foster City, California.
David Paul Morris | Bloomberg | Getty Images
Gilead Sciences will acquire the biotech company Immunomedics in a 21 billion deal that will expand the availability of Gilead cancer treatments, the companies announced on Sunday.
The deal will give access to Glid, the drug of the FDA-approved drug Trodelvi for metalstatic triple-negative breast cancer.
Gilead said it would receive Immunomidix at $ 88 per share. The offer will be hand-held with about લગભગ 15 billion in cash and 6 6 billion in newly issued funds. The transaction is expected to close in the fourth quarter of 2020, the statement said.
“This acquisition represents significant progress in Gilead’s work to build a robust and diverse oncology portfolio,” said Daniel O’Day, Gilead’s chief executive, in a statement.
“Trodelvi is a valid, mutable drug for a form of cancer that is particularly challenging to treat,” Oday said. “We will now continue to explore its potential for the treatment of many types of cancer, both as an acetherapy and with other treatments.”
Immunomidix has a market value of about 10 10 billion after the company’s shares nearly doubled this year.
This is breaking news. Please check back for updates.
.
